Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

8 Customer Reviews

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  •  

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

    WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

    P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Targets
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
CDK2/CyclinE2 [1]
(Cell-free assay)
CDK2/CyclinA [1]
(Cell-free assay)
9 nM 11 nM 15 nM >10 μM >10 μM
In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 NE[2N5dMcW6jc3WgRZN{[Xl? MVWyOEBp MWPJcohq[mm2aX;uJI9nKEOGS{SgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDSZkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECyJO69VQ>? NV;OVG82OjR4NEGxNFM>
COLO205 NWPa[YdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVy3NkBp MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvODN4IN88US=> Mo[1NlQ3PDFzMEO=
U937 M4Ht[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;HZZpzPzJiaB?= MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvOTRizszN MUSyOFY1OTFyMx?=
MOLM13 NHTTbFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWq3NkBp MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTF2xN{Bk\WyuczDoZZJjd3KrbnegSmxVOyCLVFSgcZV1[W62IHHzd4V{e2WmIHHzJIlv[2:{cH;yZZRqd25ib3[gX|NJZXSqeX3p[Ilv\SCrboTvJGRPSSC5aYToJGlEPTBib3[gNE4xQTZizszN M1z6WVI1PjRzMUCz
MOLM13 MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD1O|IhcA>? NHjjW3NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JJNwemGoZX7pZk1z\XOrc4ThcpQhcHWvYX6gUW9NVTF|IHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ49zeG:{YYTpc44hd2ZiW{PIYZRpgW2rZHnu[UBqdnSxIFTORUB4cXSqIFnDOVAhd2ZiMD6wPVYh|ryP M1jCNlI1PjRzMUCz
MDA-MB-435 Mo\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfadlEzPCCq NHH1PVBKSzVyPUCuNVYh|ryP NYjLXVlpOTV6MEG4N|E>
K562 NHz1SIVEgXSxdH;4bYMhSXO|YYm= NFzyRmI6PiCq NWm5TFBxTE2VTx?= NHjXOWxKSzVyPUKg{txO MYWyOFQyPzV4Nh?=
DU145 NUCyfI1iS3m2b4TvfIlkKEG|c3H5 NInn[Wc6PiCq MWfEUXNQ NX:5[HlTUUN3ME23MlUh|ryP M3LmclI1PDF5NU[2
MDA-MB-231 NYHpeZhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWCxJO69VQ>? NXXrVIllOjRiaB?= NFPO[3hFVVOR NVXOPYNjS2WubDDjfYNt\SCjcoLld5Qh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNm MUGyOFQyPzV4Nh?=
MCF7 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37NTVEh|ryP NIjMWpkzPCCq NWT4PVRLTE2VTx?= NEfHdIpE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U> MVqyOFQyPzV4Nh?=
MCF7 Mnz1T4lv[XOnIFHzd4F6 MWG1JO69VQ>? M4jV[FI1KGh? NHPaN2JFVVOR NHjBcnpKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzRxY4njcIlvTDFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC{ZYTpco9jdGG|dH;tZUBxcG:|cHjvdplt[XSrb36gZZQhW2W{N{iw NGTndG8zPDRzN{W2Oi=>
MDA-MB-231 NH\1c29McW6jc3WgRZN{[Xl? MlPYOUDPxE1? MlruNlQhcA>? M4\YbWROW09? M3zBXGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC= MX6yOFQyPzV4Nh?=
MDA-MB-231 MXrGeY5kfGmxbjDBd5NigQ>? NYDLcYhuOS1zMDFOwG0> MUSyOEBp NIroc4JFVVOR M1fVNYRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMhWEGUUDDjcIVifmGpZR?= NYn2dWQ6OjR2MUe1OlY>
MCF7 M2P3c2Z2dmO2aX;uJGF{e2G7 MnfNNU0yOCEQvF2= M3\COlI1KGh? NHvuOJFFVVOR NF\SVoZld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W|c3XkJIF{KFCDUmCgZ4xm[X[jZ3W= NH;6dXEzPDRzN{W2Oi=>
MDA-MB-231 M2XNU2Z2dmO2aX;uJGF{e2G7 MkPuNE42NTFizszN M1LDOlQ5KGh? NIrkVJBFVVOR M2\tTYhieyCwbzDD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm NW\U[4hVOjR2MUe1OlY>
MCF7 MomxSpVv[3Srb36gRZN{[Xl? NYiwU4tOOC53LUGg{txO NF3YUos1QCCq MnLUSG1UVw>? M2T6VYhieyCwbzDD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm M4n6flI1PDF5NU[2
697 NX\K[HVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTF2OD6zPEBvVQ>? MVfTRW5ITVJ?
P12-ICHIKAWA MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfXdZZGUUN3ME25Ok4xPCCwTR?= MVjTRW5ITVJ?
NB69 Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrlVHRKSzVyPUG2NU45KG6P NFvHS2hUSU6JRWK=
EoL-1 M3HRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Po[mlEPTB;MUi3MlI3KG6P M4PwZ3NCVkeHUh?=
BHT-101 M17SWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PkcWlEPTB;MUm4MlI2KG6P MkXhV2FPT0WU
SK-NEP-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJ{MD6wNkBvVQ>? MYnTRW5ITVJ?
MHH-NB-11 MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTJ{MD6xPUBvVQ>? M{TnWXNCVkeHUh?=
AsPC-1 Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWCyNHI{UUN3ME2yOVIvPTNibl2= NYm5cJo4W0GQR1XS
ES1 NH7QS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmW2TWM2OD1{NU[uNlUhdk1? NHKx[49USU6JRWK=
LAMA-84 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPvTWM2OD1{NUiuNVkhdk1? MV3TRW5ITVJ?
MOLT-16 MlG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnDZ|VWUUN3ME2yOVgvPDlibl2= NYrSXZFzW0GQR1XS
ES7 MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfGNmxKSzVyPUK3N{4xQSCwTR?= MX7TRW5ITVJ?
KY821 M3nzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjNTIVKSzVyPUOxOE4yKG6P NHLWNlhUSU6JRWK=
RT-112 NH3qXnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDmfId7UUN3ME2zNlEvODVibl2= NV\4[XprW0GQR1XS
HL-60 NGT0WIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjjTWM2OD1|NECuOlYhdk1? NIfiRnhUSU6JRWK=
MOLT-4 NWfGR|JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LGd2lEPTB;M{S1MlE{KG6P NIjJdJhUSU6JRWK=
KARPAS-45 NGLMc5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[y[Wk2UUN3ME2zO|YvOTZibl2= M4jQfnNCVkeHUh?=
SK-N-AS NFPoW|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDqPJRKSzVyPUO4O{45OyCwTR?= M3T6[HNCVkeHUh?=
CTB-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTRyNT6wNkBvVQ>? NVuwbnByW0GQR1XS
NKM-1 Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD1OmFKSzVyPUSxNU45QSCwTR?= M{\pfHNCVkeHUh?=
HTC-C3 MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLITWM2OD12M{KuPVUhdk1? NUXENplFW0GQR1XS
BE-13 NGXpbGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M364UGlEPTB;NES0MlI4KG6P MVHTRW5ITVJ?
KOSC-2 MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITHV41KSzVyPUS2Ok46KG6P MYDTRW5ITVJ?
NB14 Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTR6Mz61PEBvVQ>? MWDTRW5ITVJ?
CAL-27 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTTb5lKSzVyPUS5OE42QSCwTR?= MVTTRW5ITVJ?
H9 NXjBcmdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1frVGlEPTB;NEm1MlQ{KG6P M1PrWHNCVkeHUh?=
RS4-11 NF3vVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV2xVnZxUUN3ME21NFQvPzNibl2= M3nROXNCVkeHUh?=
PA-1 M2DVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne4TWM2OD13MEmuPFYhdk1? MUTTRW5ITVJ?
MV-4-11 MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVW3fmk3UUN3ME21NVMvQDVibl2= M3\NfnNCVkeHUh?=
OS-RC-2 NF2x[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTV{MT62NkBvVQ>? MojlV2FPT0WU
RPMI-8226 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vHWmlEPTB;NUK2Mlg3KG6P MVPTRW5ITVJ?
HGC-27 NHG5OoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTV4ND65PUBvVQ>? MV;TRW5ITVJ?
CHP-212 NUPNRW1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr4SFFKSzVyPUW5N{42QSCwTR?= MkTvV2FPT0WU
NB10 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzLVJBKSzVyPUW5PU4yQCCwTR?= NVS2Vmw4W0GQR1XS
HH M1naSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFqwRXBKSzVyPUW5PU41OyCwTR?= NIDr[IJUSU6JRWK=
EW-16 NGPweXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LtTWlEPTB;NkCzMlUzKG6P Mlz3V2FPT0WU
ES8 NH\RSWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfJPVZKSzVyPU[wOU4zOSCwTR?= NFXQbmtUSU6JRWK=
HAL-01 NGWzNXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFiwWZpKSzVyPU[wOU43PyCwTR?= MUHTRW5ITVJ?
A204 MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mom3TWM2OD14M{OuPVEhdk1? M2KzfnNCVkeHUh?=
MHH-PREB-1 MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LHV2lEPTB;NkO2Mlk6KG6P M2LkSHNCVkeHUh?=
EM-2 M2jTU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LQUWlEPTB;NkWwMlY1KG6P MlTMV2FPT0WU
BV-173 NXPObVI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYKydpZlUUN3ME22OVIvPDhibl2= MYjTRW5ITVJ?
ONS-76 MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3G4eGlEPTB;Nke3MlgzKG6P MUHTRW5ITVJ?
KM-H2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvPRmYxUUN3ME22PVUvPTRibl2= MUXTRW5ITVJ?
D-263MG NYjXcnNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrzVXBKSzVyPUexO{4yOiCwTR?= NET0dmxUSU6JRWK=
ES3 MlqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTd{OD65N{BvVQ>? NUL6N|FUW0GQR1XS
VA-ES-BJ NYDMenVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHOb3NIUUN3ME23N|IvOjdibl2= MnzOV2FPT0WU
NBsusSR MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3m0N2lEPTB;N{SyMlk6KG6P MXHTRW5ITVJ?
NCI-H520 M3zPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDFe|FMUUN3ME23OFYvPTJibl2= M3fObHNCVkeHUh?=
ES5 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7oXpA3UUN3ME23OVIvQCCwTR?= NGfIbmZUSU6JRWK=
T-24 Mof4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoeyTWM2OD15N{iuO|Ehdk1? NGfUVpBUSU6JRWK=
SW962 NFjCUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rifWlEPTB;OEC4MlY{KG6P MWHTRW5ITVJ?
EW-3 NV;ifXJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LIdWlEPTB;OEC4Mlc3KG6P Mkj3V2FPT0WU
RXF393 NFzVPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPRW|ZKSzVyPUixNk44QSCwTR?= NIfJfmxUSU6JRWK=
U251 NF3qb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrHe|hvUUN3ME24NVMvQDhibl2= NInVcphUSU6JRWK=
CAMA-1 M37ZcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml[1TWM2OD16M{OuPVQhdk1? M{jpbHNCVkeHUh?=
JVM-3 MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmThTWM2OD16NUGuO|ghdk1? MnvuV2FPT0WU
COLO-800 NX;RbYFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTh7Nz63PEBvVQ>? MmfmV2FPT0WU
OVCAR-5 MoD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PjU2lEPTB;OUCwMlEhdk1? NYCzUHdZW0GQR1XS
LB1047-RCC M2Dzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn2xTWM2OD17MkeuOVYhdk1? M3PxW3NCVkeHUh?=
SW954 NH76UZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO5dW9KSzVyPUmyPU41OSCwTR?= NH3vS41USU6JRWK=
J-RT3-T3-5 NVTjN3hPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\uXmlEPTB;OUO2MlA3KG6P NEW3d3dUSU6JRWK=
Mewo MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:yTWM2OD17M{[uOkBvVQ>? NIfDVm1USU6JRWK=
NCI-H1770 MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUT5cIhIUUN3ME25OFAvPTVibl2= M1LrNHNCVkeHUh?=
HO-1-N-1 M3H5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\ZTWM2OD17NkKuPFEhdk1? Mn76V2FPT0WU
HSC-3 NEH3[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfYRVZKSzVyPUm2Ok41QCCwTR?= MV7TRW5ITVJ?
TYK-nu Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrRdXBWUUN3ME25PVgvOjVibl2= NYnlfoRkW0GQR1XS
KYSE-150 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTFwMECwO|Yh|ryP M17GdXNCVkeHUh?=
SN12C MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TsS2lEPTB;MT6wNFg4PSEQvF2= NWPz[|JjW0GQR1XS
MOLT-13 NUnzbIZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\OTWM2OD1zLkCxOFIyKM7:TR?= MUfTRW5ITVJ?
TE-11 Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfzS4lKSzVyPUGuNFQ5OTJizszN MmfZV2FPT0WU
DB MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jyV2lEPTB;MT6wO|I4OyEQvF2= M2jQSHNCVkeHUh?=
CAL-39 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvJTWM2OD1zLkC3OVIzKM7:TR?= NIL0eYhUSU6JRWK=
A3-KAW NHnab2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvKUGJKSzVyPUGuNFg1ODhizszN NETXWIdUSU6JRWK=
CHP-134 NUe4eFVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\tT2lEPTB;MT6xNVgxPyEQvF2= NWrYVVRqW0GQR1XS
TGW NVWyR|hxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jPOWlEPTB;MT6xNlM6PSEQvF2= NXTEbmhVW0GQR1XS
QIMR-WIL MkLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFwMUOxN|Qh|ryP NEP5Z|lUSU6JRWK=
NCI-SNU-1 MkPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;LTWM2OD1zLkG2N|U1KM7:TR?= MYfTRW5ITVJ?
CGTH-W-1 Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[xbmlEPTB;MT6xO|E5PiEQvF2= MnnGV2FPT0WU
MHH-ES-1 NVvPVIRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M124bGlEPTB;MT6xO|k5PiEQvF2= NWHBd4xOW0GQR1XS
LB2241-RCC NHT0e2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HPNWlEPTB;MT6xPFYzKM7:TR?= Mn35V2FPT0WU
ML-2 Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGez[lhKSzVyPUGuNlA4OzRizszN M{O4WHNCVkeHUh?=
COR-L23 Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj2R2RFUUN3ME2xMlIzQTN|IN88US=> MXfTRW5ITVJ?
BFTC-905 M4K2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTFwMkSyOlch|ryP NGHId|BUSU6JRWK=
Hs-578-T MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIe5S|FKSzVyPUGuNlU5OTdizszN M4LDdnNCVkeHUh?=
KG-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nnNmlEPTB;MT6yOlY5PiEQvF2= NUi1SJVTW0GQR1XS
HEL MoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HwRmlEPTB;MT6yPVM{QCEQvF2= MYXTRW5ITVJ?
A549 NX7nTZVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnKVWNKSzVyPUGuNlk{QTlizszN MXzTRW5ITVJ?
COLO-741 MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTFwM{KwPFkh|ryP M2LZV3NCVkeHUh?=
PC-3 NILQcI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHQTmdKSzVyPUGuN|UzOjFizszN M{\NPXNCVkeHUh?=
HOS NFvte49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm4S3pKSzVyPUGuN|UzQTZizszN NH;5bpdUSU6JRWK=
HT-1080 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnm5TWM2OD1zLkO3OVE6KM7:TR?= NGjhOFhUSU6JRWK=
TE-8 MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MniwTWM2OD1zLkSxO|c1KM7:TR?= NXO4dXpYW0GQR1XS
BHY MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TCSmlEPTB;MT60OlkzOyEQvF2= M2TyfXNCVkeHUh?=
BB65-RCC Mne5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDWZ3M6UUN3ME2xMlUxPTJ6IN88US=> MojjV2FPT0WU
HN NYDWOXhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTFwNUSwO|Eh|ryP M37QUHNCVkeHUh?=
NCI-H441 NEjLWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITtNmlKSzVyPUGuOVQ6ODdizszN MojYV2FPT0WU
RPMI-8866 NV[0[JVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HrWGlEPTB;MT61PFUxPyEQvF2= M2fSbnNCVkeHUh?=
CAL-62 Mn[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjJXYJLUUN3ME2xMlYxQDZ{IN88US=> MXLTRW5ITVJ?
MG-63 MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4i5cGlEPTB;MT62NVgyOyEQvF2= NF\pXWdUSU6JRWK=
SK-LU-1 M2fDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoToTWM2OD1zLk[yNVUzKM7:TR?= Mo\uV2FPT0WU
BCPAP M3HxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LyemlEPTB;MT62OlQ2PyEQvF2= MWTTRW5ITVJ?
22RV1 M1vMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTFwNke4OFMh|ryP NVvO[IJTW0GQR1XS
T47D M2\MNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnK4TWM2OD1zLk[4NFYyKM7:TR?= MYnTRW5ITVJ?
MSTO-211H NIm3fZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXEdXhKSzVyPUGuOlk3ODNizszN Ml3DV2FPT0WU
DEL NH;tS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\wfJJKSzVyPUGuO|AzPzNizszN MYTTRW5ITVJ?
H4 MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXYR2hKSzVyPUGuO|MzOTJizszN MofGV2FPT0WU
CAL-51 M1vPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LXUGlEPTB;MT63OFg2PSEQvF2= MVzTRW5ITVJ?
ABC-1 NXH4PFRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTFwN{i1PFIh|ryP MWfTRW5ITVJ?
MZ2-MEL Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrMTWM2OD1zLke5OVQzKM7:TR?= M3PEV3NCVkeHUh?=
YKG-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFwOEGwOlEh|ryP M1Lp[HNCVkeHUh?=
KM12 MnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\XbW9KSzVyPUGuPFE3ODJizszN M{j5d3NCVkeHUh?=
L-363 NVTncld3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXH[|NxUUN3ME2xMlg4PDF{IN88US=> MVTTRW5ITVJ?
KU812 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTuV4tKSzVyPUGuPFkzQDJizszN NX3BUVRYW0GQR1XS
LOXIMVI NX7mc3dmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH4NHNKSzVyPUGuPVEzOjhizszN NXTqXXJIW0GQR1XS
G-401 M3\p[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\zbIFEUUN3ME2xMlkzPDJ6IN88US=> MXfTRW5ITVJ?
SW780 NXvSXWdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzSTWM2OD1zLkm2NlQ3KM7:TR?= NGfXcXBUSU6JRWK=
SW872 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTFwOUizN{DPxE1? NW\DRXBoW0GQR1XS
NB7 M4\BTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfKTWM2OD1zLkm5N|I{KM7:TR?= NVTmOm9zW0GQR1XS
T98G NUXmT4VHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHlR29KSzVyPUKuNFA3PjZizszN NIPZUZNUSU6JRWK=
SW1710 NF;RU|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPZVY1DUUN3ME2yMlA3QTR3IN88US=> NFvYepBUSU6JRWK=
NCI-H1573 MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnKTWM2OD1{LkC3Nlk5KM7:TR?= M1;6cXNCVkeHUh?=
KE-37 NYTFNJNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TFe2lEPTB;Mj6wPFk2OSEQvF2= M2SwWHNCVkeHUh?=
786-0 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S3dWlEPTB;Mj6xOVQ{QSEQvF2= NUfIUndtW0GQR1XS
SAS MoHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJwMkCzO|Qh|ryP MnzaV2FPT0WU
CAL-54 M3TWe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLvXmNKSzVyPUKuNlA1OTNizszN NHHNfXZUSU6JRWK=
SF268 NV3uW2oxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f3RmlEPTB;Mj6yN|EzOiEQvF2= NX;2XHdjW0GQR1XS
SW620 M3fDd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHuVYdKSzVyPUKuNlYyPjlizszN M2nFUnNCVkeHUh?=
MN-60 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;1e41KSzVyPUKuN|ExPiEQvF2= NG[3O|VUSU6JRWK=
EFO-27 MnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnOXlFKSzVyPUKuN|IxPThizszN NFfnO4hUSU6JRWK=
NCI-H747 M3\Ubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJwM{KxPVkh|ryP M3\BOnNCVkeHUh?=
HCC2218 Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHIR4dKSzVyPUKuN|U{PzRizszN NULleG5lW0GQR1XS
MIA-PaCa-2 Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTlTWM2OD1{LkO2OFM4KM7:TR?= MkPpV2FPT0WU
SJSA-1 NF7sdmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHDTWM2OD1{LkO3O|k3KM7:TR?= MU\TRW5ITVJ?
RKO MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;nfWlEPTB;Mj6zPFQ6PiEQvF2= MX3TRW5ITVJ?
NB6 NH\V[|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3G2VmlEPTB;Mj60NFM4PCEQvF2= M1XHbnNCVkeHUh?=
ES4 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJwNEW0NlIh|ryP NVnjeVQ1W0GQR1XS
EGI-1 NIK4TWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJwNE[4PFMh|ryP NUj0UpJ4W0GQR1XS
CTV-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJwNUK3O|Mh|ryP M2T1UXNCVkeHUh?=
NCI-H1355 MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3lUI9KSzVyPUKuOVU6PTFizszN MmPVV2FPT0WU
GT3TKB NH3FbXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mni2TWM2OD1{LkW5NVk6KM7:TR?= M4e4dXNCVkeHUh?=
SK-HEP-1 M4\6N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPxO5VZUUN3ME2yMlU6OjZ4IN88US=> MVvTRW5ITVJ?
GAMG NWnUSWd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjSTWM2OD1{LkW5N|k1KM7:TR?= MYnTRW5ITVJ?
SK-MES-1 M3r4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHnTHZKSzVyPUKuOlE5ODNizszN MonmV2FPT0WU
RO82-W-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILaPFZKSzVyPUKuOlIxPTdizszN M4f6RXNCVkeHUh?=
ECC10 MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{T4XmlEPTB;Mj63NFIxPiEQvF2= MkXkV2FPT0WU
MCF7 NYX5emZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDKeG03UUN3ME2yMlcyPDZ2IN88US=> MlK3V2FPT0WU
D-283MED MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\YdppKSzVyPUKuO|I1OyEQvF2= Ml:xV2FPT0WU
RPMI-7951 Ml[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDlc4Z5UUN3ME2yMlc2Pjl2IN88US=> MlHVV2FPT0WU
Ramos-2G6-4C10 Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTJwN{ewPVkh|ryP M3u1T3NCVkeHUh?=
KGN NG\2SItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorGTWM2OD1{LkixPFg1KM7:TR?= MVzTRW5ITVJ?
NUGC-3 M4\QfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\GPHhKSzVyPUKuPFI2ODVizszN Mn;aV2FPT0WU
NCI-H292 M1\3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXuXmNLUUN3ME2yMlg2ODV|IN88US=> MW\TRW5ITVJ?
Becker NEHM[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rXUWlEPTB;Mj65OVg{OiEQvF2= MXnTRW5ITVJ?
NCI-H1299 M2LvV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\wTWM2OD1|LkC1NlY{KM7:TR?= M1jHZXNCVkeHUh?=
ETK-1 MnrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTaTWM2OD1|LkC1OFMh|ryP NFjCW|NUSU6JRWK=
TK10 MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrqcZA5UUN3ME2zMlIxOTZ3IN88US=> MlvpV2FPT0WU
VMRC-RCZ MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7MTWM2OD1|LkO2OFg5KM7:TR?= M3;5UHNCVkeHUh?=
YH-13 M2ftcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnx[3FyUUN3ME2zMlQ1ODd7IN88US=> M1[wcnNCVkeHUh?=
DU-145 NUX2WWdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLLdolTUUN3ME2zMlQ3OjZ7IN88US=> M4LkWXNCVkeHUh?=
SW1088 MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTNwNEe0O{DPxE1? M3\sfHNCVkeHUh?=
HOP-92 NGnYbWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzVe3dKSzVyPUOuOVA{PDJizszN MXrTRW5ITVJ?
KP-N-YS M2PyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37zSWlEPTB;Mz62NlE{QSEQvF2= MUPTRW5ITVJ?
NCI-H460 NF\MTo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHQNYxKSzVyPUOuOlY4OyEQvF2= NVzXcHE5W0GQR1XS
U-2-OS NEDQUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYmzZno{UUN3ME2zMlczPTN3IN88US=> MUfTRW5ITVJ?
A101D M2DRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;wWHRKSzVyPUOuO|Y6OzZizszN MYjTRW5ITVJ?
MDA-MB-231 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDBSW1vUUN3ME2zMlgyQTVzIN88US=> M{XEOnNCVkeHUh?=
IST-MES1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzmTWM2OD1|LkizNkDPxE1? MlnkV2FPT0WU
COR-L105 NULyRWFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlm5TWM2OD12LkCxPEDPxE1? NY\mRY9UW0GQR1XS
NCI-H1437 NGjOPI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHrTWM2OD12LkCyN|AzKM7:TR?= MYjTRW5ITVJ?
CAL-85-1 NFPuNGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVu1Z25CUUN3ME20MlAzPDZzIN88US=> MkjqV2FPT0WU
MZ1-PC NF;WNmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\vTWM2OD12LkG4OVU3KM7:TR?= NEXpUFlUSU6JRWK=
VM-CUB-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTRwM{GyPFQh|ryP NFHFOWlUSU6JRWK=
CHL-1 M4Dibmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTRwM{KxOlkh|ryP NGrqZYZUSU6JRWK=
MDA-MB-361 NWDrOIFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\SNHZKSzVyPUSuN|MyPTNizszN MV3TRW5ITVJ?
NCI-H661 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTRwNUCwPVIh|ryP NUT1[|VZW0GQR1XS
EW-11 NULpeIh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTRwNUKyN|Eh|ryP NYD6b5BwW0GQR1XS
BEN MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTRwNUK4NVUh|ryP NES1RXVUSU6JRWK=
BFTC-909 NInJc3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTRwNU[yO|Uh|ryP NEDLdZhUSU6JRWK=
NCI-H2087 NFHuT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4X6bmlEPTB;ND61PFE3PCEQvF2= MXTTRW5ITVJ?
RVH-421 MnOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvrO2VKSzVyPUSuOlY3QSEQvF2= NVrQRWN5W0GQR1XS
P30-OHK MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTRwNkiwNFgh|ryP NVzWbYtOW0GQR1XS
NCI-H28 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW4TWM2OD12LkixOlYyKM7:TR?= M3e2b3NCVkeHUh?=
ES6 NF\pR2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD3T3FpUUN3ME20Mlg{ODF4IN88US=> NWe3c4pnW0GQR1XS
769-P MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTRwOEW5NlYh|ryP Mnv6V2FPT0WU
OE33 MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPWTWM2OD12Lki4NVYyKM7:TR?= NUDMcYlJW0GQR1XS
SW982 NF7FUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFm2N5FKSzVyPUSuPVUxPjFizszN M3nkT3NCVkeHUh?=
A388 NFHMRWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTVwMEK5PFMh|ryP NVPiVoxjW0GQR1XS
TI-73 MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrETWM2OD13LkC2NVk1KM7:TR?= MWnTRW5ITVJ?
HCT-116 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTVwMEm4PFkh|ryP MnrZV2FPT0WU
HuP-T3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDYOmZCUUN3ME21MlE5PzB7IN88US=> NYf5TINiW0GQR1XS
G-402 NUGwW|RWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHwR4FKSzVyPUWuNVk1OTZizszN NGDnXHZUSU6JRWK=
NCI-H1792 NETTRpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInqZ2FKSzVyPUWuNlQ3OjJizszN M2\F[nNCVkeHUh?=
NCI-H209 NFrzSmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\rNlVsUUN3ME21MlI2QTR{IN88US=> MX;TRW5ITVJ?
NCI-H1650 NUHOcYNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnIVY1kUUN3ME21MlMxPjN2IN88US=> NYPBe|lGW0GQR1XS
LCLC-97TM1 M13YZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7jcVBKSzVyPUWuN|E5ODhizszN NX7GR2U2W0GQR1XS
S-117 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjVOXczUUN3ME21MlM3QTd4IN88US=> NWrHW2k4W0GQR1XS
GI-ME-N NHTweodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjVTWM2OD13LkO5OlgyKM7:TR?= NXHrUpJwW0GQR1XS
NCI-H2122 NWXpeHBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;3V5lKSzVyPUWuOFk{QTdizszN MmjlV2FPT0WU
NCI-H1793 M{nlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3uxe2lEPTB;NT62O|U6OyEQvF2= NVT3S|I{W0GQR1XS
C2BBe1 NWewbopiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4KxXGlEPTB;NT63NFA5QCEQvF2= NITFUnBUSU6JRWK=
TE-12 NV3ZTGtDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf6[2ZFUUN3ME21MlgxPTV4IN88US=> NH20OnZUSU6JRWK=
LCLC-103H NUT0cnpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGf0WpNKSzVyPUWuPVE4KM7:TR?= NFzIZpJUSU6JRWK=
A673 M4nIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX1UnB3UUN3ME21MlkyQTN{IN88US=> MUPTRW5ITVJ?
BB30-HNC MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXu3fmtUUUN3ME21Mlk5OzZizszN NVvvRoh{W0GQR1XS
SF295 Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHYTWM2OD14LkCwOFIzKM7:TR?= Mk\CV2FPT0WU
KU-19-19 M{fRNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTZwMEG3N|Eh|ryP MmrkV2FPT0WU
CFPAC-1 NH3CUmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\hV2lEPTB;Nj6wOFQ1OyEQvF2= M2XOZnNCVkeHUh?=
LoVo NIjSRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3u0S2lEPTB;Nj6wOVA3OyEQvF2= NWrncYQzW0GQR1XS
8505C NGTBO|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYSyZWRSUUN3ME22MlA4PTd|IN88US=> MU\TRW5ITVJ?
GMS-10 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP3W3hKSzVyPU[uNVUxODJizszN NYjJcVB7W0GQR1XS
Ca9-22 NFL2fHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWntfHFZUUN3ME22MlE3PzFizszN M1TQZXNCVkeHUh?=
DOK M{OweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXGNYdKSzVyPU[uNlIxPzJizszN NGW4OFNUSU6JRWK=
FADU NIPXcWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHQ[4ZKSzVyPU[uNlYxOzlizszN MmCxV2FPT0WU
BxPC-3 MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M360cmlEPTB;Nj6yO|MzKM7:TR?= M{XHZ3NCVkeHUh?=
CAL-33 MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTZwMkmyNFEh|ryP NFXSbFlUSU6JRWK=
SHP-77 MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DJWWlEPTB;Nj6zNVUyOiEQvF2= NYfPOXBVW0GQR1XS
LXF-289 NH3aNFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHQR2N1UUN3ME22MlM{PDV3IN88US=> M3\rcnNCVkeHUh?=
GB-1 NUXrWm5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULxSIdDUUN3ME22MlM5OiEQvF2= NGXtSGpUSU6JRWK=
KS-1 NFOybWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTZwM{i0OFch|ryP MnfNV2FPT0WU
D-502MG MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TJPWlEPTB;Nj60NlM4PiEQvF2= MUfTRW5ITVJ?
LAN-6 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D4T2lEPTB;Nj61NVAzOyEQvF2= M4DqSHNCVkeHUh?=
H-EMC-SS MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrvNHJpUUN3ME22MlU3OTR5IN88US=> M1zTO3NCVkeHUh?=
LC-2-ad M4LvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPU[XpRUUN3ME22MlYxODd4IN88US=> Ml\HV2FPT0WU
NCI-H1693 NV3BU4RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTZwNkKyNVUh|ryP NITXcFVUSU6JRWK=
SK-N-FI NFrkVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTxXFV1UUN3ME22Mlc2ODR2IN88US=> NH\DVndUSU6JRWK=
D-423MG MoPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTZwN{[xNVch|ryP M3LuTnNCVkeHUh?=
KNS-42 NUDXVYpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\wSmlEPTB;Nj63PFE6PyEQvF2= NGe2eoRUSU6JRWK=
GCT M17DfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTZwOUO4JO69VQ>? MYLTRW5ITVJ?
DSH1 NITUUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;IPWlEPTB;Nz6wOlM{KM7:TR?= MlflV2FPT0WU
D-247MG Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fSWmlEPTB;Nz6wO|g5OSEQvF2= M2TFVnNCVkeHUh?=
NCI-SNU-5 M13tR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojhTWM2OD15LkG4N|cyKM7:TR?= M4GzVHNCVkeHUh?=
TE-6 NYDlRpV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWX6UXNTUUN3ME23MlIxPjBzIN88US=> M4C0VHNCVkeHUh?=
NOMO-1 M3PaeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLYTWM2OD15LkKyNVI4KM7:TR?= Ml\iV2FPT0WU
NB17 M4nNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTdwM{CzNFkh|ryP NVXTOmk6W0GQR1XS
EW-22 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HaWmlEPTB;Nz6zOFM1QCEQvF2= NF:0cWdUSU6JRWK=
EW-13 M3XGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1iyVGlEPTB;Nz6zOVE3OiEQvF2= M3\1V3NCVkeHUh?=
DOHH-2 M4O5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DTT2lEPTB;Nz60OFAzKM7:TR?= NVOwSlgxW0GQR1XS
TGBC1TKB NVS4[IxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHv3R4lKSzVyPUeuOFk5QTlizszN MXHTRW5ITVJ?
GR-ST NIn6SHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTdwNUK1PVQh|ryP MlrYV2FPT0WU
KYSE-520 NVy0WYoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjmNHRKSzVyPUeuOVU2OTVizszN M{XETnNCVkeHUh?=
CAPAN-1 NXHERZlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnX6TWM2OD15LkW5OVEh|ryP MUnTRW5ITVJ?
HCE-4 NIjYVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTdwNkKyO|kh|ryP MVXTRW5ITVJ?
MLMA MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTdwNkK5OVch|ryP MlXlV2FPT0WU
HT-144 NUO3d|NMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTyTWM2OD15Lk[1N|Y5KM7:TR?= M3T3bXNCVkeHUh?=
KYSE-180 MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XxW2lEPTB;Nz63NVE3QSEQvF2= Mn7ZV2FPT0WU
TE-5 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\FOYRuUUN3ME23Mlk2QTdzIN88US=> NYS0c25MW0GQR1XS
IGROV-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTdwOUi1OVEh|ryP NUD4OoF5W0GQR1XS
NCI-H1581 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HvcGlEPTB;OD6wNVIh|ryP M4nMNnNCVkeHUh?=
SW1990 M3;aRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRThwMES2OVkh|ryP MWDTRW5ITVJ?
EFM-19 M3TnRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3r6RWlEPTB;OD6wPFU1PSEQvF2= NYPlWJFTW0GQR1XS
OGR-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\RTWM2OD16LkSzNFI{KM7:TR?= NXHDRZRPW0GQR1XS
U-118-MG MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFGyeZlKSzVyPUiuOFM1PjNizszN NGrNUHJUSU6JRWK=
SK-OV-3 NHLuZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{W4eGlEPTB;OD60Olc3PSEQvF2= M2LSSnNCVkeHUh?=
KNS-62 M4LB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRThwNUG3OlEh|ryP M3nqT3NCVkeHUh?=
GOTO M4jEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37zWGlEPTB;OD61O|Y{PSEQvF2= Ml;oV2FPT0WU
8305C MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nqNWlEPTB;OD63NFQ5PCEQvF2= NV61To96W0GQR1XS
RPMI-2650 MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoizTWM2OD16LkexPVU2KM7:TR?= MoLUV2FPT0WU
NEC8 NGTMfHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPxcGpoUUN3ME24Mlc1OzB5IN88US=> NFLROZZUSU6JRWK=
KYSE-450 NGPXemJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIGycoVKSzVyPUiuPFY2PDhizszN M3f5W3NCVkeHUh?=
RMG-I MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHH0VIdKSzVyPUmuNVQxPThizszN MYfTRW5ITVJ?
CAKI-1 NYni[|hoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTlwM{G5O|kh|ryP M{fESnNCVkeHUh?=
KYSE-510 NVrSUHZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDjTWM2OD17LkO1O|c5KM7:TR?= NF3HbYhUSU6JRWK=
A4-Fuk MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEC3W4VKSzVyPUmuN|Y4ODFizszN MX3TRW5ITVJ?
AN3-CA NEnJXGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPzfG9UUUN3ME25MlQ2PDR2IN88US=> Mn;wV2FPT0WU
SK-N-DZ Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTlwN{K4OFkh|ryP MnTkV2FPT0WU
HSC-2 MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[5TWM2OD17Lke2OlI6KM7:TR?= NVHqTZlRW0GQR1XS
EW-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETQTYhKSzVyPUmuO|k{PjlizszN NVj6c|h6W0GQR1XS
D-566MG M{PZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{eyXmlEPTB;OT64N|Y3PCEQvF2= Ml3kV2FPT0WU
COLO-792 NV\oSVc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XK[2lEPTB;OT65PFc1PiEQvF2= M1:yb3NCVkeHUh?=
TE-10 Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nlXGlEPTB;MUCuNFM6PiEQvF2= M1nTN3NCVkeHUh?=
NCI-H650 NWj5[2ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHaZYRKSzVyPUGwMlQzQDZizszN M3PC[XNCVkeHUh?=
U-266 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorOTWM2OD1zMD60OVUh|ryP NIfJ[4VUSU6JRWK=
Detroit562 NEDqNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTFzLkC1NVUh|ryP NYrQNmM{W0GQR1XS
NH-12 M1XIRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jrSWlEPTB;MUGuNVQ1PiEQvF2= NFOzZoVUSU6JRWK=
CO-314 M{XBXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPWXlRFUUN3ME2xNU4zQDR{IN88US=> NF;te4VUSU6JRWK=
IST-MEL1 NYDIdYdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PpU2lEPTB;MUGuOVMzOyEQvF2= M4LJWXNCVkeHUh?=
KNS-81-FD MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLtem9YUUN3ME2xNU42PTJ5IN88US=> MYDTRW5ITVJ?
SW1463 NV7Ib4VWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFzLkW5PFkh|ryP M3\XOHNCVkeHUh?=
NCI-H23 NHHocVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XaUmlEPTB;MUGuOlU2OiEQvF2= NVnwXmk5W0GQR1XS
SK-MEL-2 M4DlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTFzLkexPVch|ryP M{iyUXNCVkeHUh?=
NB13 NVHJZmpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXr0SHYzUUN3ME2xNk4yPDl3IN88US=> Mk\SV2FPT0WU
Daoy MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTF{LkK4OVYh|ryP M1LNXHNCVkeHUh?=
NCI-H1623 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTF{LkO4NFEh|ryP NYH5e3BxW0GQR1XS
NMC-G1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPTTWM2OD1zMj63NVch|ryP M{DKenNCVkeHUh?=
DK-MG NYfBe4hsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HPdWlEPTB;MUKuPVQ5OiEQvF2= M2\D[XNCVkeHUh?=
TCCSUP NF;3b2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXEb|ZKSzVyPUGzMlEzQDRizszN MYnTRW5ITVJ?
SCC-15 NVPp[npLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIq4R4lKSzVyPUGzMlI3PTFizszN MYTTRW5ITVJ?
NOS-1 M3;6OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYK4b|VzUUN3ME2xN{4zQDl|IN88US=> NFLKZpFUSU6JRWK=
RH-1 NEi3VJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLrfIg2UUN3ME2xN{4{ODN5IN88US=> MkjCV2FPT0WU
SK-MEL-3 NHzVW3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4X5[GlEPTB;MUOuN|czQCEQvF2= MmLEV2FPT0WU
NB5 Mnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXoOHVzUUN3ME2xN{41ODZ5IN88US=> NF7nWnRUSU6JRWK=
SNU-387 NXHQZnRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W0cGlEPTB;MUOuOVA4OiEQvF2= MW\TRW5ITVJ?
CAL-120 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTF|Lk[3NVgh|ryP M13QVHNCVkeHUh?=
Mo-T MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF|LkewO{DPxE1? MkW4V2FPT0WU
LNCaP-Clone-FGC MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoO1TWM2OD1zMz63PVkzKM7:TR?= M{P3bnNCVkeHUh?=
CAN MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvHTWM2OD1zND6wNlg5KM7:TR?= NGTMeGZUSU6JRWK=
SK-MEL-30 NGnKSnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PFXGlEPTB;MUSuNFY{KM7:TR?= MV7TRW5ITVJ?
COLO-678 NHzXblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvRRXo5UUN3ME2xOE4xQDJ{IN88US=> NXnpTGNZW0GQR1XS
SCC-9 NWG2eYpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTF2LkGwNlEh|ryP NWHrRXF5W0GQR1XS
KINGS-1 NWm1fIRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XZU2lEPTB;MUSuNVQxOiEQvF2= MWLTRW5ITVJ?
SL-513 MnHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LnXGlEPTB;MUSuNVg4KM7:TR?= NXnrOYh1W0GQR1XS
HLE MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPNTWM2OD1zND6zPFUzKM7:TR?= NU\WSW85W0GQR1XS
SW1573 NV7yXYVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTF2LkS0N|Uh|ryP MorWV2FPT0WU
KYSE-140 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrWTWM2OD1zND62N|I4KM7:TR?= Mo\FV2FPT0WU
SK-PN-DW NWjVcYlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfjRXNKSzVyPUG0MlgxODFizszN MX;TRW5ITVJ?
A253 NHHV[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXsSVR{UUN3ME2xOU4xPjJ3IN88US=> MUPTRW5ITVJ?
CAL-12T MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7tPIplUUN3ME2xOU41PjZ{IN88US=> NILiPI9USU6JRWK=
COLO-679 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF3Lke2PFMh|ryP MYHTRW5ITVJ?
UACC-257 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;wTWM2OD1zNj6xNlAyKM7:TR?= NUjiOGF6W0GQR1XS
U-87-MG NVK1fpZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTF4LkO1NlMh|ryP Mm\iV2FPT0WU
HCC1806 MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTF4LkewO|Eh|ryP MVfTRW5ITVJ?
NCI-H2170 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTF5LkK0OFgh|ryP MmPEV2FPT0WU
AGS MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrTcFFKSzVyPUG3MlM5ODhizszN MXzTRW5ITVJ?
MEL-HO MkDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzLVoxPUUN3ME2xO{44PTB|IN88US=> MkDaV2FPT0WU
SW48 M1rPS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXCb2xEUUN3ME2xO{44PzF4IN88US=> MXHTRW5ITVJ?
HuP-T4 M37IXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF6LkCyNFYh|ryP M1[x[XNCVkeHUh?=
NCI-H720 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzQeVFKSzVyPUG4MlE1ODJizszN MlGzV2FPT0WU
RCC10RGB NGrHd3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPZTWM2OD1zOD6xOlk4KM7:TR?= NV7tVFdWW0GQR1XS
HD-MY-Z MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjzPFdYUUN3ME2xPE4zOjV2IN88US=> NHPVRoNUSU6JRWK=
A427 M1nKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFmxWlhKSzVyPUG4MlUxQTRizszN M2r3UHNCVkeHUh?=
HCC2998 MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jDdWlEPTB;MUiuOlA2OSEQvF2= MnjGV2FPT0WU
EPLC-272H M4DYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1KydWlEPTB;MUmuNFQ{PCEQvF2= Mm\LV2FPT0WU
C32 M1LZd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF7LkC0OUDPxE1? NYDXWZF7W0GQR1XS
UMC-11 M1PJV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnmTWM2OD1zOT6yNVI{KM7:TR?= M1vYSHNCVkeHUh?=
CaR-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTF7Lk[4NFQh|ryP MmPxV2FPT0WU
KYSE-410 NVzOUFBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEK0SZBKSzVyPUG5MlkyOzlizszN MnjBV2FPT0WU
HuCCT1 NYDueHA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT3TWM2OD1{MD62Nlk1KM7:TR?= NVnHVnVJW0GQR1XS
LB996-RCC M3u4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTJyLkexOlgh|ryP MkDEV2FPT0WU
KYSE-70 NH;nZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVu2ZVA2UUN3ME2yNE45ODV7IN88US=> MXzTRW5ITVJ?
CAL-72 M1fDNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHjVJhKSzVyPUKwMlkyPSEQvF2= NWnybG5[W0GQR1XS
Capan-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7RRllkUUN3ME2yNU4xPDF|IN88US=> NFXwb2pUSU6JRWK=
PANC-08-13 NH7rd3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK3dnM{UUN3ME2yNU4zPTF3IN88US=> Mm\2V2FPT0WU
SBC-1 M1\kOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIP6WXhKSzVyPUKxMlMxQDFizszN NEfzd4dUSU6JRWK=
MFM-223 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzxT3NwUUN3ME2yNU4{OzR{IN88US=> NUeydZQ3W0GQR1XS
BB49-HNC M{XFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHoTWM2OD1{MT61O|E3KM7:TR?= M1jpWHNCVkeHUh?=
SH-4 NE\EWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHSzWYhKSzVyPUKxMlY3OThizszN NHK0RWdUSU6JRWK=
HuO9 NHXLNZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fTcmlEPTB;MkGuPVgzPSEQvF2= MXXTRW5ITVJ?
AM-38 M37jTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LCVWlEPTB;MkKuNFQ5PSEQvF2= M2PQc3NCVkeHUh?=
A431 NWLnPFJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJ|LkKxNVkh|ryP NF\jT3JUSU6JRWK=
YAPC NGDHXndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIe5TXZKSzVyPUKzMlI3PTFizszN NU\ZR4Z6W0GQR1XS
LU-139 Mnq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYCyd3lVUUN3ME2yN{41QDB7IN88US=> NHnk[2RUSU6JRWK=
HEC-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7lTWM2OD1{Mz60PVM4KM7:TR?= M{G2bnNCVkeHUh?=
SCC-25 M{\DWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJ2LkOwNFYh|ryP MlG2V2FPT0WU
HT-29 NVXo[GE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDUR2JKSzVyPUK0MlM5OjNizszN MX;TRW5ITVJ?
PC-14 MmH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTJ2Lk[1O|Eh|ryP M1y5dnNCVkeHUh?=
Calu-6 NGe1e4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX31XVdSUUN3ME2yOU42ODdzIN88US=> M3vaTnNCVkeHUh?=
SJRH30 NULSXYhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDKTWM2OD1{NT62OFk3KM7:TR?= MVLTRW5ITVJ?
ChaGo-K-1 NVvlUmdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJ4LkG2Nlkh|ryP M3LFPXNCVkeHUh?=
IA-LM MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHuTWM2OD1{Nj6zOlQ2KM7:TR?= MnrBV2FPT0WU
GP5d NE\PUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fLV2lEPTB;Mk[uOFQ6OSEQvF2= NHfNXZZUSU6JRWK=
NCI-H2291 NEKwXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJ4Lk[1OFEh|ryP NVjhNFJpW0GQR1XS
BALL-1 NVzGSIRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJ4LkmzPVch|ryP Mo\LV2FPT0WU
HCC1954 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJ4Lkm4NFgh|ryP NHL6VXRUSU6JRWK=
NCI-H2452 M{XmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJ5LkSxOlMh|ryP NHvpZXhUSU6JRWK=
LU-99A MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf2cW5uUUN3ME2yO{42PTh{IN88US=> M{SwPXNCVkeHUh?=
NTERA-S-cl-D1 NFS0[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDCTWM2OD1{Nz63Nlk6KM7:TR?= M3LvVnNCVkeHUh?=
PANC-10-05 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTJ5Lke3O|Uh|ryP NXfH[IdrW0GQR1XS
NCI-H2405 MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmKzTWM2OD1{Nz65N|g4KM7:TR?= M2Hl[nNCVkeHUh?=
MDA-MB-415 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\MTWM2OD1{OD60NVM4KM7:TR?= M3:0enNCVkeHUh?=
NCI-H2342 NHfycGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PQbWlEPTB;MkiuOVI5OSEQvF2= MoTNV2FPT0WU
TGBC24TKB NVezXnRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPkeZRNUUN3ME2yPE44OTF5IN88US=> NYrXd4VwW0GQR1XS
LU-134-A M{L0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;u[pZKSzVyPUK4MlkzPjFizszN M13jXHNCVkeHUh?=
SCC-4 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjqeHJDUUN3ME2zNU4xPDl2IN88US=> M{\pU3NCVkeHUh?=
Saos-2 NWn3cIdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;lN5RKSzVyPUOxMlk{ODZizszN MnTCV2FPT0WU
RERF-LC-MS MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\uPHhwUUN3ME2zNk45OjNzIN88US=> M{jvXXNCVkeHUh?=
M14 M4TGfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPOTYZKSzVyPUOyMlk4PjRizszN M2D3dXNCVkeHUh?=
HPAF-II NUf3cZFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojRTWM2OD1|Mz61NFEyKM7:TR?= MnjaV2FPT0WU
NCI-H1755 NH[4SlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkSxTWM2OD1|ND6zN|A2KM7:TR?= NHvYe|hUSU6JRWK=
D-392MG M2qyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn33TWM2OD1|NT64Olc1KM7:TR?= MnLWV2FPT0WU
A704 M3fJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DtPGlEPTB;M{[uNFQzPyEQvF2= Mn[0V2FPT0WU
CP50-MEL-B NWLReZdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnCTWM2OD1|Nj6xPVEyKM7:TR?= NF3QbWtUSU6JRWK=
EW-18 NE\VdnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n2cWlEPTB;M{[uOFUzKM7:TR?= NV23[ZEyW0GQR1XS
WM-115 NEnLSI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PXSGlEPTB;M{[uPFA6QSEQvF2= NUXVSplMW0GQR1XS
LU-65 NUnPTYEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTN5LkG0NVch|ryP M1vQ[HNCVkeHUh?=
NCI-H1563 NUXhbYVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\mdmlEPTB;M{euNlQ5PCEQvF2= M1XVXHNCVkeHUh?=
DBTRG-05MG M{fhO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfaUHd{UUN3ME2zPE4xPjlzIN88US=> M4i2NHNCVkeHUh?=
NCI-H630 M3O2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojLTWM2OD1|OD60O|E1KM7:TR?= NYPPfGxwW0GQR1XS
NCI-H1155 NVLKWldbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fTUmlEPTB;M{muNlQzKM7:TR?= M4e0VHNCVkeHUh?=
OVACR-3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTN7LkmxPVUh|ryP MkX1V2FPT0WU
OAW-42 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTRyLkSyOVgh|ryP M4n3NHNCVkeHUh?=
JVM-2 NXWyUlJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkflTWM2OD12MT6yOFE2KM7:TR?= NF7oN3hUSU6JRWK=
C3A NXvOVHNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHOT4dKSzVyPUSxMlM1PDdizszN MkLuV2FPT0WU
HT55 NXXTN5pWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3uxd2lEPTB;NEKuNlg1OSEQvF2= NXHndpFKW0GQR1XS
OVCAR-4 NFPTeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPUTWM2OD12Mj6yPVc1KM7:TR?= MXfTRW5ITVJ?
MEG-01 MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzsV3hRUUN3ME20Nk41PjF4IN88US=> NFK1dXBUSU6JRWK=
NCI-H82 NXy1cYhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHW1U|lKSzVyPUSzMlk5QTJizszN M2HlNnNCVkeHUh?=
JEG-3 M3nNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljZTWM2OD12ND65OFch|ryP NG[5VZlUSU6JRWK=
BPH-1 MnzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrN[pFKSzVyPUS2MlM6QThizszN NWG5NI5{W0GQR1XS
MPP-89 NXzFbI8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDOc2RKSzVyPUS3MlI5QThizszN NFTQTnRUSU6JRWK=
ALL-PO MkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{SxcGlEPTB;NEeuOFE5QCEQvF2= M1HXOHNCVkeHUh?=
HT MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLQWXdlUUN3ME20O{41QTJizszN MnPtV2FPT0WU
NCI-H2347 NX3QbJdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Wyc2lEPTB;NEiuNFcyPSEQvF2= NX[1Zo5LW0GQR1XS
A2780 M3HrUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLTXGxKSzVyPUS5MlQzOjhizszN M3;OOnNCVkeHUh?=
KARPAS-299 NXP4R4lCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXpfWdKSzVyPUS5MlUyOTlizszN MW\TRW5ITVJ?
NCI-H1651 M2TJZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\pb2lEPTB;NEmuPFgzOSEQvF2= MlnNV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research:

[1]

+ Expand
  • Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • Dosages: 0-150 mg/kg
  • Administration: Given by gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol <1 mg/mL
In vivo Saline 20 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT02907918 Not yet recruiting Breast Cancer|Cancer of Breast|Breast Carcinoma Washington University School of Medicine|Pfizer February 28, 2017 Phase 2
NCT01209598 Completed Sarcoma|Liposarcoma Memorial Sloan Kettering Cancer Center|Pfizer September 23, 2010 Phase 2
NCT03054363 Not yet recruiting Breast Cancer University of Colorado, Denver March 2017 Phase 1|Phase 2
NCT03024489 Not yet recruiting Head and Neck Cancer|Locally Advanced|Unresectable Mahidol University February 2017 Phase 1|Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID